Trastuzumab-Qyyp (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- TRAZIMERA
Contraindications
None.
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections of the label: •Cardiomyopathy [see Warnings and Precautions (5.1)] •Infusion Reactions [see Warnings and Precautions (5.2)] •Embryo-Fetal Toxicity [see Warnings and Precautions (5.3)] •Pulmonary Toxicity [see Warnings and Precautions (5.4)] •Exacerbation of Chemotherapy-Induced Neutropenia [see Warnings and Precautions (5.5)]
Drug Interactions
Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products estimated long washout period [see Clinical Pharmacology (12.3)]. If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, closely monitor the patient’s cardiac function.
Mechanism of Action
The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab products have been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Trastuzumab products are mediators of antibody-dependent cellular cytotoxicity (ADCC). In vitro, trastuzumab product-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.